Top Markets
Coin of the day
ENvizion Medical Ltd. ENvizion Medical Ltd.

ENvizion Medical Ltd.

ENVM
Rank in Stocks #40141
ENvizion Medical Ltd. is a specialized medical device enterprise. Its primary... ENvizion Medical Ltd. is a specialized medical device enterprise. Its primary product is the ENvue system, which streamlines the placement of feeding tubes. This innovative system achieves accuracy by integrating navigation capabilities with advanced sensors and detailed body mapping. Founded in 2017, the company maintains its headquarters in Tel Aviv-Yafo, Israel.
Share Price
$0.1500484
Last synced: 2024-03-18
Market Cap
$234.01K
Change (1 day)
0.80%
Change (1 year)
0.00%
Country
IL
Trade ENvizion Medical Ltd. (ENVM)

Category

P/E ratio for ENvizion Medical Ltd. (ENVM)
P/E ratio as of 2026 TTM: 0
According to ENvizion Medical Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ENvizion Medical Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
33.99 -
US
33.47 -
US
21.39 -
IE
18.84 -
US
49.47 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.